![PDF) Utilization and efficacy of second-line targeted therapy in metastatic renal cell carcinoma: Data from a national registry PDF) Utilization and efficacy of second-line targeted therapy in metastatic renal cell carcinoma: Data from a national registry](https://i1.rgstatic.net/publication/321988624_Utilization_and_efficacy_of_second-line_targeted_therapy_in_metastatic_renal_cell_carcinoma_Data_from_a_national_registry/links/5a3c6fb3a6fdcc21d878031f/largepreview.png)
PDF) Utilization and efficacy of second-line targeted therapy in metastatic renal cell carcinoma: Data from a national registry
![Cancers | Free Full-Text | Cytoreductive Nephrectomy and Overall Survival of Patients with Metastatic Renal Cell Carcinoma Treated with Targeted Therapy—Data from the National Renis Registry Cancers | Free Full-Text | Cytoreductive Nephrectomy and Overall Survival of Patients with Metastatic Renal Cell Carcinoma Treated with Targeted Therapy—Data from the National Renis Registry](https://www.mdpi.com/cancers/cancers-12-02911/article_deploy/html/images/cancers-12-02911-g001.png)
Cancers | Free Full-Text | Cytoreductive Nephrectomy and Overall Survival of Patients with Metastatic Renal Cell Carcinoma Treated with Targeted Therapy—Data from the National Renis Registry
![Cancers | Free Full-Text | Outcomes According to MSKCC Risk Score with Focus on the Intermediate-Risk Group in Metastatic Renal Cell Carcinoma Patients Treated with First-Line Sunitinib: A Retrospective Analysis of 2390 Cancers | Free Full-Text | Outcomes According to MSKCC Risk Score with Focus on the Intermediate-Risk Group in Metastatic Renal Cell Carcinoma Patients Treated with First-Line Sunitinib: A Retrospective Analysis of 2390](https://www.mdpi.com/cancers/cancers-12-00808/article_deploy/html/images/cancers-12-00808-g001.png)